Since the incidence of mucosal melanoma is higher in the Japanese population compared to Caucasians, and since mucosal melanoma possesses a lower mutation burden compared to cutaneous melanoma, the efficacy of anti-PD1 antibody (Ab) monotherapy for mucosal melanoma is limited. Therefore, other targeting molecules that enhance the anti-tumor effects of immune checkpoint inhibitors are needed. In this report, we present a case with anti-PD1 Ab-resistant recurrent malignant melanoma of the nasal cavity successfully treated with nivolu-mab, ipilimumab plus denosumab combination therapy.
|Number of pages||5|
|Journal||Case Reports in Oncology|
|Publication status||Published - 2020|
- Bone metastasis
- Mucosal melanoma
- Nivolumab plus ipilimumab combination therapy
ASJC Scopus subject areas